Login Fachkreise
Therapie der Anämie
Leitlinien
Aapro MS, Link H: Update 09/2007/EORTC guidelines/anemia management/erythro-poiesisstimulating agents. Oncologist 2008; 13 (suppl 3): 33–6; Aktualisierung 2012 in Vorbereitung
Bundesärztekammer: Querschnitts-Leitlinien zur Ther. mit Blutkomponenten und Plasmaderivaten, 4. Aufl. 2008
Engelhardt M et al: Behandlung mit hämatopoetischen Wachstumsfaktoren. Stand: 11/2008. www.dgho.de
Bokemeyer C et al. EORTC guidelines/use of erythropoietic proteins/anaemic patients with Cancer: 2006 update. Eur J Cancer 2007; 43: 258–70. Leitlinie der DKG (Kurzfassung: www.onkosupport.de)
Rizzo JD et al: ASCO/ASH/clinical practise guideline/epoetin and darbepoetin/adult patients with cancer. J Clin Oncol 2010; 28: 4996–10
Literatur
- Aapro MS: Editorial: anemia management with erythropoiesis-stimulating agents: a risk-benefit update. Oncologist 2008; 13 (suppl 3): 1–3
- Bastit L: Randomized, multicenter, controlled trial comparing the efficacy and safety of darbepoetin alpha administered every 3 weeks with or without intravenous iron in patients with chemotherapy-induced anemia. J Clin Oncol 2008; 26:1611–8
-
Engert A et al: Epoetin alfa in patients with advanced-stage Hodgkin's Lymphoma: Results of the randomized placebo-controlled GHSG HD15EPO Trial. J Clin Oncol 2010; 28: 2239–45
-
Ganz T: Hepcidin and iron regulation, 10 years later. Blood 2011; 117: 4425–33
-
Koch CG et al: Duration of red-cell storage and complications after cardiac surgery. N Engl J Med 2008; 358: 1229–39
- Pedrazzoli P: Randomized trial of intravenous iron supplementation in patients with chemotherapy-related anemia without iron deficiency treated with darbepoetin alpha. J Clin Oncol 2008; 26: 1619–25
-
Swift S et al: Absence of functional EpoR expression in human tumor cell lines. Blood 2010; 115: 4254–63.
-
Rodgers GM: Cancer- and chemotherapy-induced anemia. NCCN Clinical Practice Guidelines in Oncology 2011 Available from: URL: http://www.nccn.org
Onkologie 2012/13
Newsletter